VINBLASTINE 10 mg Vial

Antimicrotubule Antineoplastic Agent – Vinca Alkaloid Class

ATC Code: L01CA01 | Prescription Only | Cytotoxic

---

Product Description:

Vinblastine is a vinca alkaloid antineoplastic agent derived from the periwinkle plant (Catharanthus roseus). It exerts its cytotoxic activity by inhibiting microtubule formation in the mitotic spindle, thereby arresting cell division in the metaphase of the cell cycle. As a cell cycle–specific agent (M phase), Vinblastine is a cornerstone in various multi-agent chemotherapy regimens for hematologic malignancies, solid tumors, and immune-modulated cancers. It is administered intravenously and requires careful handling due to its vesicant nature.

Available Presentation:

• Strength: 10 mg per vial
• Formulation: Lyophilized powder for solution for injection
• Packaging: Single-dose vial in individual carton
• Route of Administration: Intravenous (IV) injection only
• Dilution Required: Must be reconstituted with sterile 0.9% sodium chloride solution
• Storage Conditions: Store at 2°C to 8°C; protect from light; do not freeze

Uses:

• Hematologic Oncology:
  • Part of ABVD regimen in Hodgkin’s lymphoma
  • Used in combination therapies for non-Hodgkin’s lymphoma and multiple myeloma
• Solid Tumors:
  • Effective in testicular cancer, breast cancer, and Kaposi’s sarcoma
  • Off-label or adjunctive protocols for gestational trophoblastic neoplasia, bladder cancer, and neuroblastoma

Indications:

• Hodgkin’s Disease and Non-Hodgkin’s Lymphoma
• Advanced Testicular Germ Cell Tumors
• Choriocarcinoma and other gestational trophoblastic diseases
• Kaposi’s Sarcoma (HIV-associated or classical forms)
• Breast Carcinoma
• Miscellaneous cancers as part of multidrug protocols under institutional oncology guidelines

Regulatory and Safety Profile:

• ATC Code: L01CA01
• Pharmacologic Class: Vinca Alkaloid / Antimicrotubule Agent
• Pregnancy Category: D – Avoid unless benefit outweighs risk
• Black Box Warning: For intravenous use only – fatal if administered intrathecally
• Common Side Effects: Leukopenia, fatigue, nausea, mucositis, alopecia, constipation
• Severe Adverse Reactions: Myelosuppression, neurotoxicity (peripheral neuropathy), vesicant tissue necrosis if extravasation occurs
• Monitoring Parameters: CBC with differential, hepatic function, signs of neurotoxicity, infusion-site inspection

---

Contact our team at info@panamfarma.com to request documentation or to include Vinblastine in oncology regimen tenders or clinical protocol bundles.